DV Biomed (Taiwan) Insiders
| 6539 Stock | TWD 66.80 0.20 0.30% |
DV Biomed employs about 316 people. The company is managed by 11 executives with a total tenure of roughly 63 years, averaging almost 5.0 years of service per executive, having 28.73 employees per reported executive. Recap of DV Biomed's management performance can provide insight into the venture performance.
| Liqi Zhang Chairman Chairman of the Board, General Manager |
6539 |
DV Biomed Management Team Effectiveness
The company has return on total asset (ROA) of 8.85 % which means that it generated a profit of $8.85 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on equity (ROE) of 23.52 %, meaning that it generated $23.52 on every $100 dollars invested by stockholders. DV Biomed's management efficiency ratios could be used to measure how well DV Biomed manages its routine affairs as well as how well it operates its assets and liabilities.DV Biomed Workforce Comparison
DV Biomed Co is number one stock in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is presently estimated at about 856. DV Biomed totals roughly 316 in number of employees claiming about 37% of equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of 16.64 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 14.88 %, which suggests for every 100 dollars of sales, it generated a net operating income of $14.88. DV Biomed Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. DV Biomed Price Series Summation is a cross summation of DV Biomed price series and its benchmark/peer.
DV Biomed Notable Stakeholders
A DV Biomed stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as DV Biomed often face trade-offs trying to please all of them. DV Biomed's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting DV Biomed's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Liqi Zhang | Chairman of the Board, General Manager | Profile | |
| Xiumei Xie | Chief Financial Officer, Head of Finance | Profile | |
| Yiyun Li | Chief Operating Officer | Profile | |
| Qunzhi Chen | Independent Director | Profile | |
| Peter Hou | Independent Director | Profile | |
| RongChun Lin | Independent Director | Profile | |
| Senxiong Zhang | Independent Director | Profile | |
| Qingjun Huang | Deputy General Manager-Administration Division | Profile | |
| Mingtong Chen | Director | Profile | |
| Jiaqi Zhang | Director | Profile | |
| Mingfeng He | Head of Finance & Accounting | Profile |
About DV Biomed Management Performance
The success or failure of an entity such as DV Biomed often depends on how effective the management is. DV Biomed management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of 6539 management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the 6539 management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
DV Biomed Co., Ltd. manufactures and sells medical-grade skin care products in Taiwan and internationally. The company was founded in 2011 and is based in Taipei, Taiwan. UnicoCell operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange.
Please note, the imprecision that can be found in DV Biomed's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of DV Biomed Co. Check DV Biomed's Beneish M Score to see the likelihood of DV Biomed's management manipulating its earnings.
DV Biomed Workforce Analysis
Traditionally, organizations such as DV Biomed use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare DV Biomed within its industry.DV Biomed Manpower Efficiency
Return on DV Biomed Manpower
| Revenue Per Employee | 5.7M | |
| Revenue Per Executive | 164.5M | |
| Net Income Per Employee | 953.8K | |
| Net Income Per Executive | 27.4M |
Additional Tools for 6539 Stock Analysis
When running DV Biomed's price analysis, check to measure DV Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DV Biomed is operating at the current time. Most of DV Biomed's value examination focuses on studying past and present price action to predict the probability of DV Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DV Biomed's price. Additionally, you may evaluate how the addition of DV Biomed to your portfolios can decrease your overall portfolio volatility.